Drug intelligence / Profile preview

Mai Zhuni Wuxibai

Development stage: Preclinical
Lead developer: Xinjiang Huasidan Pharmaceutical Research
Administration: Oral

Overview

Mai Zhuni Wuxibai is a traditional Uyghur medicine (ethnic medicine) compound preparation currently in preclinical development by Xinjiang Huasidan Pharmaceutical Research. It is formulated as a classic "Majun" (electuary), which is a traditional semi-solid dosage form in Uyghur medicine. The drug is being developed for the treatment of urinary tract inflammation. As a classic formula compound preparation, it likely contains multiple herbal ingredients, such as *Smilax china* (Ushba), intended to provide synergistic anti-inflammatory and antimicrobial effects.

Other names: 买朱尼吾西拜Majun Ushba

Beyond the preview

Go deeper on Mai Zhuni Wuxibai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mai Zhuni Wuxibai.

Explore the full profile